Patients Undergoing Continuous Venovenous Hemodiafiltration: Effects of Increased Blood Flow

NAActive, not recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 9, 2023

Primary Completion Date

January 9, 2023

Study Completion Date

September 30, 2024

Conditions
Acute Kidney Injury
Interventions
OTHER

Effects of increased blood flow during regional anticoagulation with 4% trisodium citrate in patients undergoing continuous venovenous hemodiafiltration

"Patients will be exposed to continuous venovenous renal therapy with distinct blood flows in 2 periods, to be defined by draw. The control group will have a flow of 150ml/min and the intervention group 250ml/min. Therapy is intended for a period of 72 hours (maximum defined by the manufacturer); with a 6-hour washout and, after that, the arm is changed to be exposed to the other blood flow."

Trial Locations (1)

Unknown

Hospital Israelite Albert Einstein, São Paulo

All Listed Sponsors
lead

Hospital Israelita Albert Einstein

OTHER